SEC Comment Letter for EXAGEN INC. (XGN) (CIK 0001274737) (XGN) — Nov 16, 2020
EXAGEN INC. (XGN) (CIK 0001274737)
Date: Nov. 16, 2020 · CIK: 0001274737 · Accession: 0000000000-20-010950
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-250015
Letter
United States securities and exchange commission logo November 16, 2020 Kamal Adawi Chief Financial Officer Exagen Inc. 1261 Liberty Way Vista, California 92081 Re:Exagen Inc. Registration Statement on Form S-3 Filed November 10, 2020 File No. 333-250015 Dear Mr. Adawi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Abby Adams at (202) 551-6902 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Matthew T. Bush, Esq.
Show Raw Text
United States securities and exchange commission logo
November 16, 2020
Kamal Adawi
Chief Financial Officer
Exagen Inc.
1261 Liberty Way
Vista, California 92081
Re:Exagen Inc.
Registration Statement on Form S-3
Filed November 10, 2020
File No. 333-250015
Dear Mr. Adawi:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Abby Adams at (202) 551-6902 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Matthew T. Bush, Esq.